GSK plc (NYSE:GSK) Holdings Decreased by Rothschild Investment LLC

Rothschild Investment LLC trimmed its stake in shares of GSK plc (NYSE:GSK) by 30.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,876 shares of the pharmaceutical company’s stock after selling 5,140 shares during the quarter. Rothschild Investment LLC’s holdings in GSK were worth $402,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC raised its holdings in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC raised its holdings in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its stake in shares of GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after buying an additional 833,080 shares in the last quarter. Miller Howard Investments Inc. NY bought a new stake in shares of GSK in the 4th quarter worth $23,366,000. Finally, Bridgewater Associates LP raised its stake in shares of GSK by 107.3% in the 3rd quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock worth $39,483,000 after buying an additional 500,010 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on GSK. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Morgan Stanley started coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

Shares of NYSE:GSK opened at $38.39 on Wednesday. The company’s fifty day moving average is $34.76 and its two-hundred day moving average is $37.30. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.92. The company has a market cap of $79.56 billion, a P/E ratio of 24.14, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 annualized dividend and a yield of 4.10%. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is currently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.